Compare KEQU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | CHRS |
|---|---|---|
| Founded | 1906 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 177.7M |
| IPO Year | 1995 | 2014 |
| Metric | KEQU | CHRS |
|---|---|---|
| Price | $35.26 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 2.1K | ★ 1.0M |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $60.79 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $32.00 | $1.09 |
| 52 Week High | $46.70 | $2.62 |
| Indicator | KEQU | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 47.16 |
| Support Level | $35.14 | $1.31 |
| Resistance Level | $35.35 | $1.51 |
| Average True Range (ATR) | 1.10 | 0.07 |
| MACD | -0.26 | -0.00 |
| Stochastic Oscillator | 46.57 | 16.67 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.